Small molecule · developed by Minerva Neurosciences
MIN-117 (also coded WF-516) is an oral capsule formulation studied in major depressive disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03446846 | Phase 2 | Major Depressive Disorder | Completed | NERV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Major Depressive Disorder
Updated Oct 25, 2026. Something wrong or missing? Report it on the NERV page.
See NERV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NERV catalysts and pipeline →